LINKING ABERRANT CHROMATIN FEATURES IN CHRONIC LYMPHOCYTIC LEUKEMIA TO DEREGULATED TRANSCRIPTION FACTOR NETWORKS
EHA Learning Center, Viola Meyer-Pannwitt, 214579
RED CELL EFFECTS OF THE ANTI-CD47 MONOCLONAL ANTIBODY HU5F9-G4 IN A PHASE I STUDY FOR RELAPSED OR PRIMARY REFRACTORY ACUTE MYELOID LEUKEMIA
EHA Learning Center, Charlotte Brierley, 214624
SPECIFICATION OF HEMATOPOIETIC STEM CELL FATE VIA MODULATION OF MITOCHONDRIAL ACTIVITY
EHA Learning Center, Mukul Girotra, 214627
MYD88 CONSTITUTIVE ACTIVATION IS DIRECTLY ABLE TO INDUCE INDOLENT LYMPHOPLASMACYTIC LYMPHOMA WITH MONOCLONAL IGM PEAK SECRETION IN 1 YEAR OLD MICE: A MODEL FOR WALDENSTROM'S MACROGLOBULINEMIA
EHA Learning Center, Christelle Vincent-Fabert, 214646
CELL OF ORIGIN AND GENOMIC PROFILE OF PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA DETERMINED USING THE NANOSTRING LST ASSAY AND ULTRA DEEP TARGETED NEXT GENERATION SEQUENCING
EHA Learning Center, Csaba Bödör, 214647
TCR ALPHA GENE REARRANGEMENTS AS A NEW TYPE OF CLONAL MARKERS IN PEDIATRIC T-LINEAGE ACUTE LYMPHOBLASTIC LEUKEMIA
EHA Learning Center, Alexander Komkov, 215246
COHESIN GENES MUTATIONS IN ACUTE LYMPHOBLASTIC LEUKEMIA
EHA Learning Center, Grazia Fazio, 215248
EVALUATION OF SAMPLE QUALITY AND CREATION OF DATABASES FOR FOLLOW-UP ASSESSMENT OF BLAST INFILTRATION AT DAY +15 IN CHILDHOOD B CELL ACUTE LYMPHOBLASTIC LEUKEMIA.
EHA Learning Center, Pablo Manresa Manresa, 215249
ENHANCING MANAGEMENT OF PH+ ALL BY MONITORING WITH AN ANALYTICALLY VALIDATED MULTIPLEX ASSAY FOR BCR-ABL1 MINOR BREAKPOINT (E1A2) WITH HIGHLY SENSITIVE DETECTION OF 1:40,000 (0.0025% OR 4.6 LOGS)
EHA Learning Center, Justin Brown, 215264
THE RISK OF DEVELOPING HEPATIC TOXICITY FROM PEGYLATED-ASPARAGINASE IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS IS HIGHLY AFFECTED BY CONCOMITANT MEDICATIONS
EHA Learning Center, Paola Minetto, 215265
CELL OF ORIGIN INFLUENCES DISEASE AGGRESSIVENESS AND CHEMOTHERAPY RESISTANCE IN A MOUSE MODEL OF MLL-AF9 REARRANGED ACUTE MYELOID LEUKEMIA
EHA Learning Center, Chi Nguyen, 215266
NUP98-KDM5A FUSION GENE IS AN INDEPENDENT PREDICTOR OF POOR PROGNOSIS WITH A DISTINCT HOX GENE EXPRESSION PATTERN
EHA Learning Center, Sanne Noort, 215280
TARGETED THERAPY FOR AML EXPRESSING SOMATIC OR GERMLINE MUTATION IN RUNX1
EHA Learning Center, Kapil Bhalla, 215281
DECIPHERING THE GENETIC LANDSCAPE OF ACUTE MYELOID LEUKEMIA WITH COMPLEX KARYOTYPE BY TRANSCRIPTOME ANALYSIS USING RNA SEQUENCING
EHA Learning Center, Frank Rücker, 215282
FURTHER EVIDENCE FOR GPR56, BUT NOT CLL-1 (CLEC12A) AS A MARKER FOR LEUKEMIC STEM CELLS IN CD34-POSITIVE ACUTE MYELOID LEUKEMIA
EHA Learning Center, Albert Wölfler, 215297
MOLECULAR ABNORMALITIES IN THERAPY-RELATED ACUTE MYELOID LEUKEMIAS
EHA Learning Center, Gueorgui Balatzenko, 215298
CD123 REDIRECTED NK92 CELLS FOR ACUTE MYELOID LEUKEMIA
EHA Learning Center, Li Zhou, 215299
A PHASE II STUDY OF THE AURORA A KINASE INHIBITOR ALISERTIB COMBINED WITH 7+3 INDUCTION CHEMOTHERAPY IN PATIENTS WITH HIGH-RISK ACUTE MYELOID LEUKEMIA
EHA Learning Center, Amir Fathi, 215313
ADMINISTRATION OF BPX-501 CELLS FOLLOWING ALPHA/BETA T-CELL AND B-CELL-DEPLETED HLA HAPLOIDENTICAL HSCT (HAPLO-HSCT) IN CHILDREN WITH ACUTE MYELOGENOUS LEUKEMIA
EHA Learning Center, Neena Kapoor, 215314
COMPARISON BETWEEN MULTIPARAMETRIC FLOW CYTOMETRY AND RT-QPCR ASSAY IN EVALUATING MINIMAL RESIDUAL DISEASE BEFORE ALLOGENEIC STEM CELL TRANSPLANTATION IN NPM1 ACUTE MYELOID LEUKEMIA
EHA Learning Center, Chiara Caprioli, 215315
ABSOLUTE LYMPHOCYTE COUNT RECOVERY AFTER INDUCTION REMISSION THERAPY IS A STRONG PREDICTOR OF OVERALL SURVIVAL IN ADULT ACUTE MYELOID LEUKAEMIA
EHA Learning Center, Joana Infante, 215329
TYROSINE KINASE INHIBITORS (TKI) IN RELAPSED/REFRACTORY (RR) PATIENTS WITH FLT3-ITD POSITIVE ACUTE MYELOID LEUKEMIA (AML) CONFER BETTER SURVIVAL THAN CHEMOTHERAPY, DUE TO A BETTER SAFETY PROFILE.
EHA Learning Center, Giovanni Marconi, 215330
ADDITION OF BORTEZOMIB TO AML-LIKE TREATMENT FOLLOWED BY NMA ALLO-SCT IN PATIENTS WITH BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM
EHA Learning Center, Elisabeth Tolley, 215331
REAL-TIME CELL-OF-ORIGIN SUBTYPE IDENTIFICATION BY GENE EXPRESSION PROFILING IN PATIENTS WITH ABC-TYPE DLBCL IN THE PHASE III TRIAL OF LENALIDOMIDE + R-CHOP (R2-CHOP) VS PLACEBO + R-CHOP (ROBUST)
EHA Learning Center, Annalisa Chiappella, 215345
EXCELLENT OUTCOMES OF OLDER PATIENTS WITH PCNSL USING R-MPV/ARA-C IMMUNOCHEMOTHERAPY WITHOUT WHOLE BRAIN RADIOTHERAPY (WBRT)
EHA Learning Center, Gareth Gregory, 215346
FIRST REPORT ON A SUCCESSFUL SCREENING PROGRAM FOR MYC REARRANGEMENTS AND A PROSPECTIVE CLINICAL TRIAL BASED ON MYC REARRANGEMENT IN NEWLY DIAGNOSED DLBCL PATIENTS IN THE NETHERLANDS
EHA Learning Center, Martine Chamuleau, 215347
CLINICAL CHARACTERISTICS AND PROGNOSTIC FACTORS OF HEMOPHAGOCYTIC SYNDROME IN ADULT PATIENTS: A RETROSPECTIVE SINGLE-CENTER STUDY FROM SINGAPORE
EHA Learning Center, Shin-Yeu ONG, 215361
THE IMPACT OF DIFFERENT IMMUNOCHEMOTHERAPY REGIMENS ON SURVIVAL OUTCOMES IN 131 NEWLY DIAGNOSED PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA
EHA Learning Center, Gayane Tumyan, 215362
TREATMENT OF TRAUMATIC BLEEDS WITH RECOMBINANT FACTOR XIII-A2 IN PATIENTS WITH CONGENITAL FXIII-A SUBUNIT DEFICIENCY: RESULTS FROM THE MENTOR™6 STUDY
EHA Learning Center, Jolanta Klovaite, 215363
DYNAMICS OF CMV AND EBV LOADS AFTER IMMUNOSUPPRESSIVE TREATMENT WITH RABBIT ATG AND CYCLOSPORINE IN ADULT APLASTIC ANEMIA: A PROSPECTIVE OBSERVATIONAL STUDY
EHA Learning Center, Jong Wook Lee, 215377
PHASE 2 STUDY OF X4P-001: A TARGETED ORAL THERAPY FOR PATIENTS WITH WHIM SYNDROME
EHA Learning Center, David Dale, 215378
SCREENING FOR TELOMERE DISEASE IS IMPORTANT TO IMPROVE THE OUTCOME OF HSCT IN PEDIATRIC PATIENTS SUFFERING FROM SEVERE APLASTIC ANEMIA.
EHA Learning Center, Iris Nederlof, 215379
DUAL MTOR KINASE INHIBITORS SYNERGIZE WITH IBRUTINIB TO INDUCE CLL APOPTOSIS, AND OVERCOME BCR- AND STROMAL-MEDIATED SURVIVAL ADVANTAGES CONFERRED IN THE MICROENVIRONMENT
EHA Learning Center, Michael Moles, 215393
DEVELOPMENT OF SELECTIVE CASEIN KINASE 1 DELTA/EPSILON INHIBITORS FOR CANCER THERAPY
EHA Learning Center, Michaela Gregorova, 215394
NEXT-GENERATION SEQUENCING AND CRISPR/CAS9 APPLICATION TO ELUCIDATE THE IMPLICATIONS OF TP53 MUTATIONS IN DEL(13Q) CHRONIC LYMPHOCYTIC LEUKEMIA
EHA Learning Center, Miguel Quijada Alamo, 215396
EVALUATION OF THE CLL-IPI IN PREVIOUSLY UNTREATED CLL PATIENTS RECEIVING CHEMO-IMMUNOTHERAPY AS FIRST-LINE TREATMENT: ANALYSIS OF 845 CASES.
EHA Learning Center, Massimo GENTILE, 215410
SPONTANEOUS CLINICAL REGRESSION IN CHRONIC LYMPHOCYTIC LEUKEMIA: CLINICAL AND BIOLOGIC FEATURES OF 27 NEW CASES FROM THE EUROPEAN RESEARCH INITIATIVE ON CLL (ERIC) INTERNATIONAL REGISTRY
EHA Learning Center, Ilaria Del Giudice, 215411
A PROGNOSTIC TOOL FOR THE IDENTIFICATION OF EARLY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS AT IMMINENT RISK OF PROGRESSION
EHA Learning Center, Lodovico Terzi di Bergamo, 215412
THE UNCOVERING OF A BCR-ABL1 TYROSINE KINASE-INDEPENDENT SIGNATURE REVEALS NEW POTENTIAL THERAPEUTIC TARGETS IN CHRONIC MYELOID LEUKAEMIA STEM CELLS
EHA Learning Center, Mhairi Copland, 215426
OPTIMAL TIME POINT FOR BCR-ABL1 KD MUTATION ANALYSIS IN CML PATIENTS; BASED ON 2013 ELN GUIDELINE
EHA Learning Center, Young Rok Do, 215427
CLONAL SELECTION DETERMINES RESULTANT DOMINANCE OF TYROSINE KINASE INHIBITOR-RESISTANT CELLS IN CHRONIC MYELOID LEUKAEMIA
EHA Learning Center, Benjamin Leow, 215428
CHRONIC MYELOID LEUKEMIA ITALIAN MULTICENTER OBSERVATIONAL STUDY (CML-IT-MOS): ANALYSIS OF CLINICAL CHARACTERISTICS OF 1330 CML PATIENTS TREATED IN REAL-LIFE IN 66 ITALIAN CENTERS OF THE GIMEMA GROUP
EHA Learning Center, Giorgina Specchia, 215442
IMATINIB STOP STUDY FEASIBLE TO JAPANESE CLINICAL SETTING.
EHA Learning Center, Kensuke Usuki, 215443
THE TARGET UK STUDY: AN EVALUATION OF TYROSINE KINASE INHIBITOR RESPONSE MONITORING PATTERNS AND REAL-WORLD MOLECULAR RESPONSE RATES IN UK PATIENTS WITH CHRONIC MYELOID LEUKAEMIA
EHA Learning Center, Adam Mead, 215444
NOVEL RNA CONSTRUCT INCREASES PERFORIN AND GRANZYME B IN NATURAL KILLER AND CYTOTOXIC T CELLS
EHA Learning Center, Arnika Wagner, 215459
THE REDUCTION OF GRAFT-VERSUS-HOST DISEASE AND TRANSFUSIONAL NEEDS AFTER THE APPLICATION OF MESENCHYMAL STEM CELL THERAPY FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
EHA Learning Center, Hajnalka Andrikovics, 215460
IMMUNOGENICITY OF TISAGENLECLEUCEL IN RELAPSED/ REFRACTORY (R/R) B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) AND DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) PATIENTS
EHA Learning Center, Theodore Laetsch, 215461
ROLE OF SPHINGOLIPID SIGNALING IN HEMATOPOIETIC STEM AND PROGENITOR CELL MOBILIZATION
EHA Learning Center, Alexander Carpinteiro, 215475
TELOMERASE TRANSCRIPTS FLOATING IN CANCER-DERIVED EXOSOMES REPROGRAM THE MICRORNA TRANSCRIPTOME PROFILE OF THE RECIPIENT CELLS
EHA Learning Center, Daniela Likonen, 215476
ALTERATIONS IN STROMAL PRECURSOR CELLS IN THE BONE MARROW OF PATIENTS WITH LEUKEMIA IN THE ONSET OF THE DISEASE AND AFTER TREATMENT
EHA Learning Center, Nataliya Petinati, 215477
THE IMPACT OF CXCR4 MUTATION SUBTYPES IN THE RESPONSE AND PROGRESSION-FREE SURVIVAL OF PATIENTS WITH WALDENSTROM MACROGLOBULINEMIA TREATED WITH IBRUTINIB
EHA Learning Center, Jorge Castillo, 215491
IBRUTINIB SHOWS PROLONGED PROGRESSION-FREE SURVIVAL IN SYMPTOMATIC, PREVIOUSLY TREATED PATIENTS WITH MYD88 MUTATED WALDENSTROM'S MACROGLOBULINEMIA: LONG-TERM FOLLOW-UP OF PIVOTAL TRIAL (NCT01614821).
EHA Learning Center, Steven Treon, 215492
IMPROVED DEPTH OF RESPONSE WITH INCREASED FOLLOW-UP FOR PATIENTS (PTS) WITH WALDENSTRÖM MACROGLOBULINEMIA (WM) TREATED WITH BRUTON’S TYROSINE KINASE (BTK) INHIBITOR ZANUBRUTINIB
EHA Learning Center, Judith Trotman, 215493
OUTCOME OF HIGH RISK FEBRILE NEUTROPENIC PATIENTS WITH GUT COLONIZATION WITH CARBAPENEM RESISTANT ENTEROBACTERIACEAE(CRE) IN SURVEILLANCE CULTURES "
EHA Learning Center, Sweta Lunkad, 215508
COLONIZATION WITH MULTIDRUG-RESISTANT BACTERIA (MDRB) IS ASSOCIATED WITH COMPLICATIONS AND POOR OUTCOME AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)
EHA Learning Center, Chiara Maria DELLACASA, 215509
ANTIBIOTICS CAN SAFELY BE DISCONTINUED IN NEUTROPENIC HEMATOLOGY PATIENTS: A PROSPECTIVE COHORT
EHA Learning Center, Zoe Van de Wyngaert, 215510
DIAGNOSIS OF HEREDITARY HAEMATOLOGICAL DISEASES USING NEXT GENERATION SEQUENCING PANELS
EHA Learning Center, Mayka Sanchez Fernandez, 215525
HEMATOPOIETIC IMPROVEMENT AFTER DEFERASIROX TREATMENT IN A CHILD WITH APLASTIC ANEMIA
EHA Learning Center, Gizem Ersoy, 215526
TREATMENT WITH FERRIC CARBOXYMALTOSE FOR SEVERE IRON DEFICIENCY ANEMIA IN STABLE NOT ACTIVELY BLEEDING PATIENTS IN THE EMERGENCY DEPARTMENT
EHA Learning Center, Irene Motta, 215527
ALTERED CARBONYLATION PATTERN IN MYELODISPLASTIC SYNDROMES
EHA Learning Center, Alba Rodríguez García, 215541
EXPRESSION LEVEL OF SPECIFIC MIRNAS BEFORE AZACITIDINE THERAPY INITIATION MAY PREDICT FUTURE EFFICACY OF THE TREATMENT IN MYELODYSPLASTIC SYNDROMES AND ACUTE MYELOID LEUKEMIA
EHA Learning Center, Michaela Dostalova Merkerova, 215542
MULTICENTRIC VALIDATION OF THE “MONOCYTE ASSAY” FOR CHRONIC MYELOMONOCYTIC LEUKEMIA DIAGNOSIS BY FLOW CYTOMETRY
EHA Learning Center, Orianne Wagner-Ballon, 215543
CLINICAL IMPACT ON THE THERAPEUTIC STRATEGY ADAPTED TO THE MUTATIONAL PROFILE IN PATIENTS WITH MYELODYSPLASTIC SYNDROME ASSOCIATED WITH DEL(5Q)
EHA Learning Center, Carolina Alarcón-Payer, 215557
CHRONIC MYELOMONOCYTIC LEUKEMIA TREATED WITH 5-AZACYTIDINE. RESULTS FROM THE HELLENIC 5-AZACYTIDINE REGISTRY.
EHA Learning Center, Panagiotis Diamantopoulos, 215558
CD96 (TACTILE) NEGATIVELY REGULATES THE CYTOTOXIC FUNCTIONS OF NATURAL KILLER CELLS AGAINST MULTIPLE MYELOMA
EHA Learning Center, Michael O'Dwyer, 215574
GLUTAMINE-DEPENDENCE TARGETING BY ASPARAGINASE SIGNIFICANTLY INCREASES ANTI-MM ACTIVITY OF PROTEASOME INHIBITION
EHA Learning Center, Paola Minetto, 215575
EVALUATION OF THE ACTIVITY OF IMIDS IN MM PROLIFERATING CELLS
EHA Learning Center, Joan Ballesteros, 215590
ADDITION OF VORINOSTAT TO LENALIDOMIDE MAINTENANCE IN NEWLY DIAGNOSED MYELOMA DOES NOT IMPROVE OUTCOMES: RESULTS OF THE MYELOMA XI TRIAL
EHA Learning Center, Matthew Jenner, 215591
EFFICACY AND TOLERABILITY OF DARATUMUMAB AFTER ALLOGENEIC TRANSPLANTATION FOR HEAVILY TREATED MULTIPLE MYELOMA.
EHA Learning Center, Ana González Rodríguez, 215606
CHARACTERISTICS, TREATMENT PATTERNS, AND SURVIVAL OUTCOMES OF PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) IN NORTH AMERICA AND EUROPE: FINDINGS FROM THE PREAMBLE STUDY
EHA Learning Center, Ravi Vij, 215607
SELINEXOR COMBINED WITH LOW DOSE BORTEZOMIB AND DEXAMETHASONE (SVD) INDUCES A HIGH RESPONSE RATE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (MM)
EHA Learning Center, Nizar Bahlis, 215622
THE MAJORITY OF NEWLY DIAGNOSED MYELOMA PATIENTS DO NOT FULFIL THE INCLUSION CRITERIA IN CLINICAL PHASE III TRIALS
EHA Learning Center, Tobias Klausen, 215623
A PHASE II STUDY OF SELINEXOR(KPT-330) COMBINED WITH BORTEZOMIB AND DEXAMETHASONE (SVD) FOR INDUCTION AND CONSOLIDATION FOR PATIENTS WITH PROGRESSIVE OR REFRACTORY MULTIPLE MYELOMA: THE SELVEDEX TRIAL
EHA Learning Center, A Broijl, 215638
LONG-TERM OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
EHA Learning Center, Qaiser Bashir, 215639
LONG-TERM OUTCOME OF PATIENTS WITH SPLANCHNIC VEIN THROMBOSIS AND MYELOPROLIFERATIVE NEOPLASMS: A SINGLE CENTER EXPERIENCE
EHA Learning Center, Danijela Lekovic, 215654
GENDER EFFECT ON PHENOTYPE AND GENOTYPE IN PATIENTS WITH POST-POLYCYTHEMIA VERA AND POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS: RESULTS FROM THE MYSEC PROJECT
EHA Learning Center, Daniela Barraco, 215655
TREATMENT STRATEGIES FOR POLYCYTHEMIA VERA: OBSERVATIONS IN A DUTCH ‘REAL-WORLD’ COHORT STUDY
EHA Learning Center, Peter Westerweel, 215670
PREGNANCY OUTCOMES IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS – PALG (POLISH ADULT LEUKEMIA GROUP) A RETROSPECTIVE ANALYSIS
EHA Learning Center, Bozena Sokolowska, 215671
INFLUENCE OF PLASMA EBV LOAD ON PROGNOSIS OF HIV-RELATED LYMPHOMAS
EHA Learning Center, Jose-Tomas Navarro, 215687
NUCLEOLIN ENHANCED ADRIAMYCIN RESISTANCE VIA THE REGULATION OF BCL-2 EXPRESSION IN CA46 BURKITT’S LYMPHOMA CELLS
EHA Learning Center, Jianda Hu, 215688
RAISED EXPRESSION OF APRIL IN THE PLATELET WITH IMMUNE THROMBOCYTOPENIA AND ITS CLINICAL IMPLICATIONS
EHA Learning Center, Yunfeng Hao, 215704
EVALUATION OF HIT SYNDROME WITH AN AUTOMATED IMMUNOASSAY IN CORRELATION WITH THE 4T SCORE IN CARDIOVASCULAR PATIENTS
EHA Learning Center, Theoni Kanellopoulou, 215705
THE ROLE OF MENTAL AND BEHAVIORAL DISORDERS IN LEUKEMIA PREDISPOSITION: A NATIONWIDE CASE-CONTROL STUDY
EHA Learning Center, Hanna Moisander-Joyce, 215721
IMPACT OF CMV PROPHYLAXIS ON RATES OF REHOSPITALIZATION IN ADULT CMV SEROPOSITIVE ALLOGENEIC HSCT RECIPIENT: EXPERIENCE FROM THE LETERMOVIR PHASE 3 CLINICAL TRIAL
EHA Learning Center, Jonathan SCHELFHOUT, 215722
IMPACT OF LOW GRADE ADVERSE EVENTS OF TYROSINE KINASE INHIBITORS ON THE QUALITY OF LIFE OF PATIENTS TREATED FOR CHRONIC MYELOID LEUKEMIA
EHA Learning Center, S.M.Amine BENLAZAR, 215737
HEME-INDUCIBLE LIPID OXIDATION PATTERN SUPPORTS MONITORING OF CELL-FREE HEMOGLOBIN ACTIVITY IN PATIENTS WITH SICKLE CELL DISEASE.
EHA Learning Center, Jeremy Deuel, 215738
ELTROMBOPAG TO IMPROVE PLATELET RECOVERY IN HAPLOIDENTICAL STEM CELL TRANSPLANTS (HAPLO-SCT): RESULTS OF A PHASE II TRIALPLUS A COMPARISON TO CONTROL PATIENTS
EHA Learning Center, Uday Popat, 215754
ASSOCIATION OF SOCIO-ECONOMIC FACTORS WITH SURVIVAL OF PATIENTS WHO EXPERIENCE SEVERE CLASSIC ACUTE GVHD AFTER ALLO-HSCT. A RETROSPECTIVE STUDY BY THE TRANSPLANT COMPLICATIONS WORKING PARTY, EBMT
EHA Learning Center, Andrzej Frankiewicz, 215755
PHASE 2, OPEN-LABEL STUDY OF DEFIBROTIDE FOR PREVENTION OF ACUTE GVHD FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT)
EHA Learning Center, Selim Corbacioglu, 215770
PROGNOSTICATION OF CHRONIC GRAFT VERSUS HOST DISEASE: THE IMPACT OF IMMUNE RECONSTITUTION.
EHA Learning Center, Fabio Serpenti, 215771
CLOFARABINE- BASED CYTOREDUCTIVE TREATMENT FOLLOWED BY MYELOABLATIVE CONDITIONING AND ALLOGENEIC STEM CELL TRANSPLANTATION IN CHILDREN WITH HIGH-RISK, RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES.
EHA Learning Center, DIEGO MEDINA VALENCIA, 215786
SELECTIVE INHIBITION OF OXIDATIVE PHOSPHORYLATION PREVENTS LETHAL GRAFT-VERSUS-HOST DISEASE WHILE MAINTAINING ANTITUMOR IMMUNITY
EHA Learning Center, Zachariah McIver, 215787
NEW OCCURRENCES OF MACROSCOPIC MYOCARDIAL FIBROSIS IN THALASSEMIA AT LONG TERM BY MULTIPLE FOLLOW-UP
EHA Learning Center, Alessia Pepe, 215802
COMMON LINK BETWEEN BONE AND HEART HEALTH IN THALASSEMIA MAJOR.
EHA Learning Center, Alessia Pepe, 215803
PLATELET MAPPING BY THROMBOELASTOGRAPHY- ASSESSMENT OF PLATELET INHIBITION SECONDARY TO ANTIPLATELET THERAPY AFTER PCI
EHA Learning Center, DIBYENDU DE, 215819
IMMATURE PLATELET FRACTION: A USEFUL MARKER FOR IDENTIFYING THE CAUSE OF THROMBOCYTOPENIA AND PREDICTING PLATELET RECOVERY
EHA Learning Center, Eunyup Lee, 215820
GAU-PED STUDY: UPDATE ON RESULTS AND LONG-TERM OUTCOME OF PATIENTS WITH GAUCHER DISEASE DIAGNOSED THROUGH A PAEDIATRIC ALGORITHM
EHA Learning Center, William Morello, 215899
ENHANCED BONE MARROW HOMING OF NATURAL KILLER CELLS FOLLOWING MRNA TRANSFECTION WITH GAIN-OF-FUNCTION CXCR4
EHA Learning Center, Emily Levy, 215900
INSUFFICIENT RECEPTOR EDITING LEADS TO DEFECTIVE B CELL CENTRAL TOLERANCE IN PRIMARY IMMUNE THROMBOCYTOPENIA (ITP)
EHA Learning Center, Zi Sheng, 215915
LABORATORY CHARACTERIZATION OF PATIENTS WITH (SUSPECTED) INHERITED PLATELET DISORDERS: RESULTS FROM THE ‘THROMBOCYTOPATHY IN THE NETHERLANDS’ STUDY
EHA Learning Center, Maaike Blaauwgeers, 215916

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings